Liquid biopsy, the detection of tumor-related DNA in the peripheral blood, is currently the best available technological tool to improve clinical decision making in precision oncology.1 Liquid biopsy currently has enough analytic and clinical validity to be implemented in routine practice for advanced disease genotyping to predict the benefit of targeted drugs. An additional great promise of the measurement of circulating tumor DNA (ctDNA) has been its use for the detection of the so-called minimal residual disease, particularly after surgical therapy to remove primary tumors, as a predictor of residual disease and relapse and as an indicator of poor prognosis.2,3 . . .
Funding and Disclosures
Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.
This editorial was published on June 4, 2022, at NEJM.org.
Print Subscriber? Activate your online access.